|
|
Article: US FTC clears way for Cephalon's acquisition of CIMA.(Federal Trade Commission)(CIMA LABS Inc.)(Brief Article)
- Article from:
- Pharma Marketletter
- Article date:
- August 16, 2004
CopyrightCOPYRIGHT 2004 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Almost a year since it outbid aaiPharma for CIMA Labs, Cephalon says that the US Federal Trade Commission has accepted a consent agreement that clears the way for it to complete its $385 million acquisition of CIMA (Marketletter September 1, 2003). The companies expect the transaction to close within the next few days.
Frank Baldino, chief executive of Cephalon, said: "we are pleased with the decision of the FTC, and we look forward to combining CIMA's operations into our business. We have been successfully serving the pain care market with ACTIQ (oral transmucosal fentanyl citrate) for a number of years; ...